Skip to main content
. Author manuscript; available in PMC: 2022 May 1.
Published in final edited form as: Dev Biol. 2021 Feb 16;473:119–129. doi: 10.1016/j.ydbio.2021.02.005

Figure 4. RA restricts the size of the FHF and maintains the SHF progenitor population in DEAB-treated embryos.

Figure 4.

(A, B) IHC for Nkx2.5 (purple) and GFP (myl7:GFP - green) in DMSO- and DEAB-treated embryos at the 20s stage (19 hpf). The cardiac cone was sometimes delayed in forming in DEAB-treated embryos relative to DMSO-treated control embryos. Views are dorsal with anterior up. Scale bar – 100 μm. (C) Quantification of the number of Nkx2.5+/GFP+ and Nkx2.5+/GFP− cells in DMSO- and DEAB-treated embryos at the 20s stage (19 hpf). *** indicates p≤0.0004. (D) Percentage of Nkx2.5+/GFP+ and Nkx2.5+/GFP− cells within the hearts of DMSO- and DEAB-treated embryos at the 20s stage (19 hpf). (E, F) IHC for Nkx2.5 (purple) and GFP (myl7:GFP - green) in DMSO- and DEAB-treated embryos at 24 hpf. Frontal views with the arterial pole up. Arrows indicate the border between Nkx2.5+/GFP+ and Nkx2.5+/GFP− cells. Scale bar – 100 μm. (G) Quantification of the number of Nkx2.5+/GFP+ and Nkx2.5+/GFP− cells in DMSO- and DEAB-treated embryos at 24 hpf. ** indicates p≤0.0060, **** indicates p<0.0001. (H) Percentage of Nkx2.5+/GFP+ and Nkx2.5+/GFP− cells within the hearts of DMSO- and DEAB-treated embryos at 24 hpf.